Eyenuk

Eyenuk is a global AI-driven digital health company specializing in autonomous eye screening technology for detection of diabetic retinopathy, age-related macular degeneration, and glaucoma. The company develops deep learning algorithms for retinal image analysis and has pioneered the EyeArt® AI Eye Screening System, the world's most extensively validated autonomous AI tool for diabetic retinopathy detection, tested on over half a million patient visits and 2 million images in real-world clinical settings. EyeArt requires no expert human grading, dilation, or specialist interpretation—enabling complete imaging, grading, and reporting within a single office visit in under 60 seconds. The system integrates a fundus camera with proprietary deep learning and image quality assessment algorithms that robustly detect disease presence and extent per internationally recognized clinical scales. EyeArt holds FDA 510(k) clearance for autonomous diabetic retinopathy detection across multiple camera platforms, EU CE marking (Class IIb MDR certification), and Health Canada licensure. Recent validation studies demonstrate 91.3% sensitivity and 91.1% specificity for referable DR, and 98.5% sensitivity for vision-threatening DR, across 100,000+ consecutive patient encounters. The platform empowers primary care physicians, endocrinologists, nurses, and technicians to perform point-of-care screening without subspecialty training, addressing the critical gap in annual diabetic retinopathy screening compliance. Eyenuk collaborates with major research institutions, health systems (including NHS deployment), and safety-net providers. Additional products under development include EyeMark™ (progression tracking), EyeArt™ AMD, EyeArt™ Glaucoma, and EyeRead™ UWF (ultra-widefield lesion analysis).